Biomatter raised US$18 million in Series A funding led by Astanor. The company designs custom enzymes for industrial customers. Existing investors UVC Partners, Inventure, and Metaplanet also participated.
Use of funds
The financing will fund a new 2,000 square meter design-and-testing facility in Vilnius. It will bring more of the build-and-test loop in-house. Biomatter will also continue investing in its computational platform and enzyme dataset.
Customers and scale
Biomatter has delivered more than 50 custom enzymes to over 25 enterprise customers across Europe, the United States, and Japan. Customers include AstraZeneca, BASF, Kirin Holdings, Neogen, Sanofi, and Tereos. Several accounts have grown from single projects into multi-year, multi-enzyme programs.
Design approach
Biomatter designs enzymes from the target reaction a customer needs, not from a natural starting enzyme. The company has generated its own enzyme data far from anything found in nature. One program produced a methylase for mRNA vaccine manufacturing that works without the expensive additive SAM.
The new Vilnius facility is scheduled to open in 2027. It is intended to shorten design-and-testing cycles from weeks to days. Biomatter also plans to grow its US presence, where about half its customers are based.